Performing the Testimonial: Rethinking Verbatim Dramaturgies

Responding to the resurgence of verbatim theatre that emerged in Britain, Australia, the United States and other parts of the world in the early 1990s, this book offers one of the first sustained, critical engagements with contemporary verbatim, documentary and testimonial dramaturgies. Offering a new reading of the history of the documentary and verbatim theatre form, the book re-locates verbatim and testimonial theatre away from discourses of the real and representations of reality and instead argues that these dramaturgical approaches are better understood as engagements with forms of truth-telling and witnessing. Examining a range of verbatim and testimonial plays from different parts of the world, the book develops new ways of understanding the performance of testimony and considers how dramaturgical theatre can bear witness to real events and individual and communal injustice through the re-enactment of personal testimony. Through its interrogation of different dramaturgical engagements with acts of witnessing, the book identifies certain forms of testimonial theatre move beyond psychoanalytical accounts of trauma and re-imagine testimony and witnessing as part of a decolonised project that looks beyond event based trauma, addressing instead of the experience of suffering wrought by racism and other forms of social injustice

Introduction (To Acting Out Trauma Special Issue)

Evoking Freud’s essay ‘Remembering, Repeating and Working Through’, first published in 1914, the title of this special issue of Performing Ethos invites us to think about the ethics of enactment and performance in relation to remembrance and the event of trauma

Performing Care: New Perspectives on Socially Engaged Performance

This edited collection brings together essays presenting an interdisciplinary dialogue between theatre and performance and the fields of care ethics, care studies, health and social care. The book advances our understanding of performance as a mode of care, challenging existing debates in this area by re-thinking the caring encounter as a performed, embodied experience and interrogating the boundaries between care practice and performance. Through an examination of a wide range of different care performances drawn from interdisciplinary and international settings, the book interrogates how performance might be understood as caring or uncaring, careless or careful, and correlatively how care can be conceptualised as artful, aesthetic, authentic or even ‘fake’ and ‘staged’. Drawing on interdisciplinary debates and discussion, the book considers how the field of performance and the aesthetic and ethico-political structures that determine its relationship with the social might be challenged by an examination of inter-human care. By placing socially-engaged performance in dialogue with theories and practices of care, the contributors consider how performance operates as a mode of caring for others and how debates between the theory and practice of care and performance making might foster a greater understanding of how the caring encounter is embodied and experienced

The VIRUS-P Exploration of Nearby Galaxies (VENGA): The X CO Gradient in NGC 628

We measure the radial profile of the ^(12)CO(1-0) to H_2 conversion factor (X_(CO)) in NGC 628. The Hα emission from the VENGA integral field spectroscopy is used to map the star formation rate (SFR) surface density (Σ_(SFR)). We estimate the molecular gas surface density (Σ_(H2)) from Σ_(SFR) by inverting the molecular star formation law (SFL), and compare it to the CO intensity to measure X_(CO). We study the impact of systematic uncertainties by changing the slope of the SFL, using different SFR tracers (Hα versus far-UV plus 24 μm), and CO maps from different telescopes (single-dish and interferometers). The observed X_(CO) profile is robust against these systematics, drops by a factor of two from R ~ 7 kpc to the center of the galaxy, and is well fit by a gradient Δlog(X_(CO)) = 0.06 ± 0.02 dex kpc^(–1). We study how changes in X_(CO) follow changes in metallicity, gas density, and ionization parameter. Theoretical models show that the gradient in X_(CO) can be explained by a combination of decreasing metallicity, and decreasing Σ_(H2) with radius. Photoelectric heating from the local UV radiation field appears to contribute to the decrease of X_(CO) in higher density regions. Our results show that galactic environment plays an important role at setting the physical conditions in star-forming regions, in particular the chemistry of carbon in molecular complexes, and the radiative transfer of CO emission. We caution against adopting a single X_(CO) value when large changes in gas surface density or metallicity are present

LSST: from Science Drivers to Reference Design and Anticipated Data Products

(Abridged) We describe here the most ambitious survey currently planned in the optical, the Large Synoptic Survey Telescope (LSST). A vast array of science will be enabled by a single wide-deep-fast sky survey, and LSST will have unique survey capability in the faint time domain. The LSST design is driven by four main science themes: probing dark energy and dark matter, taking an inventory of the Solar System, exploring the transient optical sky, and mapping the Milky Way. LSST will be a wide-field ground-based system sited at Cerro Pach\'{o}n in northern Chile. The telescope will have an 8.4 m (6.5 m effective) primary mirror, a 9.6 deg$^2$ field of view, and a 3.2 Gigapixel camera. The standard observing sequence will consist of pairs of 15-second exposures in a given field, with two such visits in each pointing in a given night. With these repeats, the LSST system is capable of imaging about 10,000 square degrees of sky in a single filter in three nights. The typical 5$\sigma$ point-source depth in a single visit in $r$ will be $\sim 24.5$ (AB). The project is in the construction phase and will begin regular survey operations by 2022. The survey area will be contained within 30,000 deg$^2$ with $\delta<+34.5^\circ$, and will be imaged multiple times in six bands, $ugrizy$, covering the wavelength range 320--1050 nm. About 90\% of the observing time will be devoted to a deep-wide-fast survey mode which will uniformly observe a 18,000 deg$^2$ region about 800 times (summed over all six bands) during the anticipated 10 years of operations, and yield a coadded map to $r\sim27.5$. The remaining 10\% of the observing time will be allocated to projects such as a Very Deep and Fast time domain survey. The goal is to make LSST data products, including a relational database of about 32 trillion observations of 40 billion objects, available to the public and scientists around the world.Comment: 57 pages, 32 color figures, version with high-resolution figures available from https://www.lsst.org/overvie

Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation

Objectives: No randomized controlled trials have yet reported an individual patient benefit of initiating combination antiretroviral therapy (cART) at CD4 counts > 350 cells/μL. It is hypothesized that earlier initiation of cART in asymptomatic and otherwise healthy individuals may lead to poorer adherence and subsequently higher rates of resistance development. Methods: In a large cohort of HIV-positive individuals, we investigated the emergence of new resistance mutations upon virological treatment failure according to the CD4 count at the initiation of cART. Results: Of 7918 included individuals, 6514 (82.3%), 996 (12.6%) and 408 (5.2%) started cART with a CD4 count ≤ 350, 351-499 and ≥ 500 cells/μL, respectively. Virological rebound occurred while on cART in 488 (7.5%), 46 (4.6%) and 30 (7.4%) with a baseline CD4 count ≤ 350, 351-499 and ≥ 500 cells/μL, respectively. Only four (13.0%) individuals with a baseline CD4 count > 350 cells/μL in receipt of a resistance test at viral load rebound were found to have developed new resistance mutations. This compared to 107 (41.2%) of those with virological failure who had initiated cART with a CD4 count < 350 cells/μL. Conclusions: We found no evidence of increased rates of resistance development when cART was initiated at CD4 counts above 350 cells/μL. HIV Medicin